Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Stomach Neoplasms 34Carcinoma, Hepatocellular 33Carcinoma, Non-Small-Cell Lung 23Colorectal Neoplasms 16Esophageal Squamous Cell Carcinoma 12Lung Neoplasms 9Rectal Neoplasms 8Nasopharyngeal Carcinoma 8Esophageal Neoplasms 6Cholangiocarcinoma 6Squamous Cell Carcinoma of Head and Neck 5Neoplasm Metastasis 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Neoplasms 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Extranodal NK-T-Cell 3Carcinoma 3Breast Neoplasms 3Spinocerebellar Degenerations 2Sarcoma 2Recurrence 2Nonsquamous Non-Small Cell Lung Cancer 2Neuroendocrine Tumors 2Lymphoma, T-Cell, Peripheral 2Locally Advanced Rectal Cancer 2

Interventions

Cyclophosphamide 34Etoposide 25Doxorubicin 20Carboplatin 20Vincristine 19Isotretinoin 19Topotecan 17Temozolomide 17Irinotecan 16Filgrastim 16Melphalan 15Cisplatin 15sargramostim 14Radiotherapy 14Granulocyte-Macrophage Colony-Stimulating Factor 133-Iodobenzylguanidine 12dinutuximab 11Peripheral Blood Stem Cell Transplantation 11naxitamab 9Thiotepa 9Magnetic Resonance Spectroscopy 9humanized 3F8 anti-GD2 monoclonal antibody 7Granulocyte Colony-Stimulating Factor 7Busulfan 7X-Rays 6Specimen Handling 6Phantoms, Imaging 6Ifosfamide 6Antilymphocyte Serum 6fludarabine phosphate 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neuroblastoma × sintilimab × Clear all
NCT06013618 2025-06-17

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

Sun Yat-sen University

Phase 2 Recruiting
120 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡